IRCT20220919055992N2 IRCT 2023-06-18 Iran University of Medical Sciences Using Hemoperfusion with HA380 Filter to Improve Heart and Liver Transplant Outcomes Safety and Feasibility Study of Using Hemoperfusion with HA380 Filter to Improve Heart and Liver Transplant Outcomes: Phase I Clinical Trial 2022-10-31 anticipated 5 Complete https://irct.ir/trial/66426 interventional Randomization: N/A, Blinding: Not blinded, Placebo: Not used, Assignment: Single, Purpose: Treatment. 1 Donors of organs and tissues. Intervention group: This group includes organ donors who will undergo hemoperfusion through the HA380 cartridge. First, sternotomy, complete separation of the aortic arch arteries and simultaneous ligation of the azygos and superior vena cava are performed, and after the preparation of the abdomen, abdominal aortic cannulation of the patients will be subjected to hemoperfusion through the HA380 cartridge. Finally, we procure the heart for donation.. Undecided - It is not yet known if there will be a plan to make this available Justification or reason for indecision in sharing IPD is There is no further information